Svra stock price target

Jan 30, 2020 · SVRA shares had a relatively better volume day versus average trading capacity of 1.76 million shares, but with a 33.21 million float and a -16.05% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for SVRA stock indicates that the average analyst price target is $5.44 per share. SVRA - Research and Analysis for SAVARA INC. - MSN Money. In-depth view of key statistics and finances for SAVARA INC. (SVRA) on MSN Money.

Savara, Inc. (SVRA) Stock Price, Quote, History & News ... Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the Company has entered into an exclusive license and collaboration agreement with Grifols for Apulmiq (inhaled liposomal ciprofloxacin). Also known as Linhaliq in Europe, Apulmiq is a late-stage investigational inhaled Selected Notes From Wall Street Analysts On Savara Inc. (SVRA) Mar 03, 2020 · On Monday, shares of Savara Inc. (NASDAQ:SVRA) marked $2.45 per share versus a previous $2.29 closing price. With having a 6.99% gain, an insight into the fundamental values of Savara Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. Analyzing Savara Inc. (SVRA) From Top to Bottom, | US Post ... Mar 16, 2020 · Additionally, SVRA shares got another “Mkt Perform” rating from JMP Securities. On August 13th, 2018, ROTH Capital Resumed an Neutral rating and increased its price target to $12. On the other hand, Ladenburg Thalmann Initiated the “Buy” rating for SVRA shares, as published in the report on January 3rd, 2018.

Savara Inc. Common Stock (SVRA) Analyst Research | Nasdaq

SAVARA INC. : SVRA Stock Price | MarketScreener Savara Inc., formerly Mast Therapeutics, Inc., is an orphan lung disease company. The Company is engaged in the development and commercialization of novel … SVRA - Savara Stock Analyst Ratings - Barchart.com Analyst Ratings for Savara Inc (SVRA) provide recommendations made by outside industry experts. Barchart provides Analyst Ratings to give you another tool to gauge the possible future performance of a stock. Analyst Ratings are available for US and Canadian equities. Analyst Target Prices. The chart at the top shows a one-year chart for Savara, Inc. (SVRA) stock price, quote, history & news ...

SVRA Stock Price & Charts | Savara

KALA - Kala Pharmaceuticals Inc Stock quote - CNNMoney.com

Stock Comparison: Compare Savara, Inc. (SVRA) to Other Stocks.

SVRA Savara Inc. Stock Quote - FINVIZ.com - Stock Screener Savara Inc. operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; and in Phase IIa development stage for treating nontuberculous mycobacterial lung infection.

Find the latest analyst research for Savara Inc. Common Stock (SVRA) at Nasdaq .com. Back to SVRA Overview. Analyst price targets provided by TipRanks.

SVRA Stock Quote - Savara Inc. Common Stock Price - Nasdaq Stock quote for Savara Inc. Common Stock Common Stock (SVRA) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq.

Dec 30, 2019 · The most recent rating by Nomura, on December 19, is at Buy, with a price target of $10.00. Ocugen, Inc. (NASDAQ: OCGN) stock surged … Savara (SVRA) Stock Falls -59.3%: How Does it Score ... Oct 02, 2019 · SVRA's score also includes a long-term technical score of 1. The fundamental score for SVRA is 66. In addition to the average rating from Wall Street analysts, SVRA stock has a mean target price of $6.33. This means analysts expect the stock to add 526.73% over the next 12 months. Click Here to get the full Stock Score Report on Savara Inc (SVRA).